News
-
-
PRESS RELEASE
New Innovative Molecular Technology Combination "LAMP + CRISPR" as CE-IVD
AmplexDiagnostics and Scope Biosciences collaborate to introduce innovative molecular technology 'eazySNP' combining LAMP and CRISPR for rapid genetic variant detection. First CE-IVD product launched for C. auris FKS1 S639 mutations -
-
-
REGULATED PRESS RELEASE
Schneider Electric announces the success of its €6.0 billion capital increase, without shareholders’ preferential subscription rights, to partially finance the acquisition of PTC Inc.
Schneider Electric successfully completes €6.0 billion capital increase to fund PTC Inc. acquisition, with new ordinary shares at €240 per share. Acquisition expected by Q3 2027 -
REGULATED PRESS RELEASE
Schneider Electric annonce le succès de son augmentation de capital de 6,0 milliards d’euros, avec suppression du droit préférentiel de souscription des actionnaires, pour financer en partie l’acquisition de PTC Inc.
Schneider Electric annonce une augmentation de capital réussie de 6,0 milliards d’euros pour financer l'acquisition de PTC Inc. Détails dans le communiqué de presse du 20 octobre 2026 -
-
-
-